



Contents lists available at ScienceDirect

Progress in Neuro-Psychopharmacology & Biological Psychiatry

journal homepage: www.elsevier.com/locate/pnp



Corrigendum

Corrigendum to “The use of cannabinoids as anticancer agents” [Prog. Neuro-Psychopharmacol. Biol. Psychiatry 64 (2016) 259–266]



Guillermo Velasco^{a,b,*}, Sonia Hernández-Tiedra^a, David Dávila^a, Mar Lorente^a

^a Department of Biochemistry and Molecular Biology I, School of Biology, Complutense University of Madrid, Spain

^b Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), Spain

The grant PI12/02248 referred in our manuscript as one of the funding sources of my lab is funded by “Instituto de Salud Carlos III” (which belongs to the Ministry and Economy and Competitiveness, MINECO) and by the European regional development funding (or “Fondo Europeo de desarrollo regional” in Spanish). However, in the acknowledgments of the manuscript we said that the work was supported “jointly by MINECO and Fondo Europeo de Desarrollo Regional (FEDER) (PI12/02248)” but we did not mention specifically the “Instituto de Salud Carlos III (ISCiii)”

Therefore, the acknowledgements section should read as follows:

“Work in G Velasco's laboratory is supported by grants from the Spanish Ministry of Economy and Competitiveness (MINECO) (PS09/01401;FR2009 0052; IT2009 0053), jointly by MINECO/Instituto de Salud Carlos III (ISCiii) and Fondo Europeo de Desarrollo Regional (FEDER) (PI12/02248.), Fundación Mutua Madrileña (AP101042012), Fundació La Marató de TV3 (20134031) and by GW Pharmaceuticals Ltd.”

DOI of original article: <http://dx.doi.org/10.1016/j.pnpbp.2015.05.010>.

* Corresponding author at: Department of Biochemistry and Molecular Biology I, School of Biology, Complutense University of Madrid, Calle José Antonio Nováis 12, 28040Madrid, Spain. Tel.: +34 913944668; fax: +34 913944672.

E-mail address: gvelasco@quim.ucm.es (G. Velasco).